IP Library Granted Patent US 10,266,808
Granted Patent B2
US 10,266,808 · App. 15/338,149 · Granted Apr 23, 2019

Method of enriching for pancreatic endocrine cells that express chromogranin A

Inventors: Olivia Kelly (San Diego, CA); Anne Bang (San Diego, CA)
Assignee: ViaCyte, Inc.
C12N5/0676C12N5/0678G01N33/56966G01N33/68C12N2501/50C12N2501/599C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,266,808
App. No.
15/338,149
Granted
Apr 23, 2019
Kind
B2
Abstract

The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.

Claims (18)

1. A method of enriching for pancreatic endocrine cells that express chromogranin A (CHGA), the method comprising:

a) exposing an in vitro population of pancreatic cells to a ligand that binds CD200, CD318, CD57, CD142, or CD340; and

b) either i) selecting cells that bind to the ligand that binds CD200, CD318, or CD57; or

ii) selecting cells that do not bind to the ligand that binds CD142 or CD340,

thereby enriching for pancreatic endocrine cells that express CHGA.

2. The method of claim 1 , wherein said ligand comprises an antibody or binding fragment thereof that specifically binds the cell-surface marker.

3. The method of claim 1 , wherein said ligand is associated with a detectable label.

4. The method of claim 1 , wherein said ligand is associated with a magnetic particle.

5. The method of claim 1 , wherein the selecting is performed by Fluorescence Activated Cell Sorting (FACS).

6. The method of claim 1 , comprising selecting cells that bind to the ligand that binds CD318, thereby enriching for pancreatic endocrine cells that express CHGA and insulin.

7. A method of enriching for pancreatic endocrine cells that express chromogranin A (CHGA), the method comprising:

a) exposing an in vitro population of pancreatic cells to a ligand that binds CD200, CD318, or CD57; and

b) selecting cells that bind to the ligand that binds CD200, CD318, or CD57,

thereby enriching for pancreatic endocrine cells that express CHGA.

8. A method of enriching for pancreatic endocrine cells that express chromogranin A (CHGA), the method comprising:

a) exposing an in vitro population of pancreatic cells to a ligand that binds CD142, or CD340; and

b) selecting cells that do not bind to the ligand that binds CD142 or CD340,

thereby enriching for pancreatic endocrine cells that express CHGA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: KELLY, OLIVIA; BANG, ANNE
To: VIACYTE, INC.
Reel/Frame 040185/0244 →
Continuity (4)
Continuation 14700608 · Apr 30, 2015
Continuation 13724556 · Dec 21, 2012
Continuation 12107020 · Apr 21, 2008
Related Publication 20170044498A1 · Feb 16, 2017